Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
New trial tests gentler chemo for Tough-to-Treat leukemia
Disease control Recruiting nowThis study compares two treatment approaches for adults whose acute myeloid leukemia has returned or not responded to initial therapy. Participants will receive either a milder, low-intensity therapy or a stronger, high-dose chemotherapy. The goal is to see if the gentler option …
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 26, 2026 03:04 UTC
-
New combo therapy aims to delay prostate cancer progression
Disease control Recruiting nowThis study is for men with prostate cancer that has spread to 1-3 small spots in the body (oligometastatic). It compares standard radiation alone to radiation followed by a targeted radioactive drug called Lu-PSMA. The goal is to see if the combination can keep the cancer from gr…
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
4,000 leukemia patients to be tracked in massive real-world study
Knowledge-focused Recruiting nowThis study will follow 4,000 people whose acute myeloid leukemia has come back or not responded to treatment. Researchers will collect information on which treatments are used and how long patients live, without giving any new medicine. The goal is to learn what works best in eve…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated May 26, 2026 03:03 UTC